Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease.
Aptamers
Coronary artery disease
Diagnostic method
Factor VIIa-Antithrombin complex
Hypercoagulopathy
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
21
08
2019
revised:
29
01
2020
accepted:
09
03
2020
pubmed:
1
4
2020
medline:
22
6
2021
entrez:
1
4
2020
Statut:
ppublish
Résumé
High plasma levels of activated Factor VII-Antithrombin complex (FVIIa-AT) have been associated with an increased risk of cardiovascular mortality in patients with stable coronary artery disease (CAD). To investigate if FVIIa-AT levels are associated with activated factor X generation (FXaG) in modified assays. Forty CAD patients were characterized for FVIIa-AT levels by ELISA and for FXaG in plasma. Novel fluorogenic FXaG assays, based on aptamers inhibiting thrombin and/or tissue factor pathway inhibitor (TFPI), were set up. FXaG correlated with FVIIa-AT levels (R High FVIIa-AT plasma levels were associated with increased FXaG. Hypercoagulability features were specifically detectable in the coagulation initiation phase, which may have implications for cardiovascular risk prediction by either FVIIa-AT complex measurement or modified FXaG assays.
Sections du résumé
BACKGROUND
High plasma levels of activated Factor VII-Antithrombin complex (FVIIa-AT) have been associated with an increased risk of cardiovascular mortality in patients with stable coronary artery disease (CAD).
OBJECTIVES
To investigate if FVIIa-AT levels are associated with activated factor X generation (FXaG) in modified assays.
PATIENTS/METHODS
Forty CAD patients were characterized for FVIIa-AT levels by ELISA and for FXaG in plasma. Novel fluorogenic FXaG assays, based on aptamers inhibiting thrombin and/or tissue factor pathway inhibitor (TFPI), were set up.
RESULTS
FXaG correlated with FVIIa-AT levels (R
CONCLUSIONS
High FVIIa-AT plasma levels were associated with increased FXaG. Hypercoagulability features were specifically detectable in the coagulation initiation phase, which may have implications for cardiovascular risk prediction by either FVIIa-AT complex measurement or modified FXaG assays.
Identifiants
pubmed: 32224381
pii: S0049-3848(20)30080-3
doi: 10.1016/j.thromres.2020.03.007
pii:
doi:
Substances chimiques
Thromboplastin
9035-58-9
Factor VIIa
EC 3.4.21.21
Thrombin
EC 3.4.21.5
Factor Xa
EC 3.4.21.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-146Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing Interest Nicola Martinelli reports receiving a payment from Diagnostica Stago, Asnieres, France, for management and conduct of the patient study. Barry Woodhams reports having been a consultant for Diagnostica Stago via Haemacon Ltd.